MAPT and Alzheimer disease: An increased CSF Tau/Aβ42 ratio is a biomarker associated with risk of aMCI and AD; increased CSF Tau reflects its release from degenerating neurons while decreased CSF Aβ42 reflects higher amyloid deposition in the brain [21,22,23,24].